BRK.B 145.06 Berkshire Hath Hld B $BRK.B Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 10:21 AM

BRK.B 145.06 Berkshire Hath Hld B $BRK.B Hit a 52 week high of 145.68 Closing the day 09:45 at 145.06 -0.46 -0.32% With a day low of 145.06 and a total volume of 212,564.

BRK.B Recent Posts: http://investorshangout.com/Berkshire-Hathaway-B-BRKB-50362/

BRK.B Berkshire Hath Hld B Recent Headline News

Tracking Lou Simpson's SQ Advisors Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Sun Nov 16, 10:03AM CST

BAM: 49.84 (+0.23), VRX: 134.94 (+0.73), LBTYK: 45.44 (-0.56), CCK: 47.94 (+0.40), WFC: 53.08 (-0.27), ORCL: 41.01 (+0.17), UPS: 106.66 (-0.17), MCO: 100.31 (-0.16), T: 35.72 (-0.18), USB: 43.70 (-0.03), TEL: 61.47 (-0.06), DTV: 87.16 (-0.39), BRK.B: 144.99 (-0.53), BRK.A: 217,385.00 (-638.00), SCHW: 28.81 (-0.06)

Does Berkshire's Duracell Deal Mean That Buffett Thinks P&G Is Overvalued?
Nicholas Ward - at Seeking Alpha - Fri Nov 14, 7:52PM CST

PG: 87.90 (-0.21), BRK.B: 144.99 (-0.53), ENR: 124.66 (-1.28)

Paying Under 2 Times EBITDA For An Industry Leader
Daniel Jones - at Seeking Alpha - Fri Nov 14, 6:51PM CST

PG: 87.90 (-0.21), BRK.B: 144.99 (-0.53), BRK.A: 217,385.00 (-638.00)

Buffett's Brilliant Duracell Deal: A Reprise Of Past Deals, A Comment On The Present Market, A Whisper About The Future
Jim Sloan - at Seeking Alpha - Fri Nov 14, 5:02PM CST

KO: 42.83 (+0.10), PSX: 72.64 (+0.86), PG: 87.90 (-0.21), BRK.B: 144.99 (-0.53), BRK.A: 217,385.00 (-638.00)

Berkshire ups GM stake, exits Deere, buys into Express Scripts
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:28PM CST

ESRX: 78.27 (+0.40), DE: 85.89 (-1.63), GM: 32.27 (+0.48), BRK.B: 144.99 (-0.53), BRK.A: 217,385.00 (-638.00)

Berkshire Hathaway to Swap Holdings in P&G for Duracell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 1:08PM CST
Warren Buffett, the CEO of Berkshire Hathaway Inc. (BRK. announced his plans of buying the battery unit Duracell of Procter & Gamble Co.
AFSI: 52.79 (+0.31), DGICA: 15.35 (+0.13), ACGL: 56.85 (-0.45), PG: 87.90 (-0.21), BRK.B: 144.99 (-0.53)

NFL's Peyton Manning Wants to Make Buying Insurance Sexy
at The Street - Fri Nov 14, 8:45AM CST
Insurance companies have turned en masse to professional athletes in an attempt to spice up a bland product.
PGR: 26.87 (-0.11), HAS: 56.50 (+2.48), NKE: 95.80 (+0.30), S: 5.01 (-0.04), MET: 54.70 (+0.17), DTV: 87.16 (-0.39), BRK.B: 144.99 (-0.53), BRK.A: 217,385.00 (-638.00), ALL: 66.47 (-0.11), MA: 84.17 (+0.12), PEP: 97.98 (+0.26)

Wall Street Breakfast: France, Germany Report Slight Growth In Q3
Wall Street Breakfast - Seeking Alpha - Fri Nov 14, 5:31AM CST
Economy France’s economy grew for the first time this year during the third quarter and Germany narrowly avoided sliding back into recession, as the two reported Q3 GDP data today. French GDP expanded by 0.3% Q/Q, above forecasts of 0.2%,...
AMZN: 323.70 (-4.12), HAL: 50.49 (-4.59), RBS: 11.86 (+0.07), ASCMA: 53.77 (-0.43), ORCL: 41.01 (+0.17), SBUX: 78.14 (+0.02), PBR: 9.72 (-0.23), SAP: 67.11 (+0.23), SPY: 204.17 (-0.07), VA: 30.63 (+0.63), QQQ: 103.13 (-0.09), BP: 40.56 (-0.38), PG: 87.90 (-0.21), BRK.B: 144.99 (-0.53), HMC: 31.52 (-0.47), BRK.A: 217,385.00 (-638.00), PLNR: 7.16 (+0.47), BHI: 66.38 (+6.49)

Warren Buffett Nabs Duracell From Procter & Gamble
Albert Alfonso - at Seeking Alpha - Thu Nov 13, 11:17PM CST

PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

Business Highlights
By The Associated Press - AP - Thu Nov 13, 4:45PM CST
___
BAC: 17.07 (-0.07), PG: 87.90 (-0.21), UBS: 17.34 (-0.20), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00), MS: 35.65 (-0.04)

Berkshire buying Duracell from P&G in $3B deal
By JOSH FUNK and MICHELLE CHAPMAN - AP - Thu Nov 13, 4:42PM CST
OMAHA, Neb. (AP) — Buying Duracell will provide a short-term charge for Warren Buffett's company, but the battery maker could eventually wind up being a drain on Berkshire Hathaway Inc. as consumers increasingly rely on rechargeable batteries.
PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

US stocks close higher as Dow Jones hits record
By BERNARD CONDON - AP - Thu Nov 13, 4:25PM CST
NEW YORK (AP) — Stocks wavered between small gains and losses on Thursday to close little changed as traders weighed generally strong earnings reports against the falling fortunes of energy companies.
HAS: 56.50 (+2.48), VIA: 74.17 (+0.83), HAL: 50.50 (-4.58), WMT: 83.22 (+0.26), PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), VIAB: 74.00 (+1.04), BRK.A: 217,385.00 (-638.00)

Warren Buffett Snags Duracell, Apple Hits All-Time High: Tech Winners & Losers
at The Street - Thu Nov 13, 4:08PM CST
Apple's market cap and share price soar to an all-time high, following a flurry of analyst upgrades. Battery maker Duracell gets snagged by Buffett and BlackBerry continues to soar.
BBRY: 10.82 (-0.38), GOOGL: 550.00 (-5.19), PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00), AAPL: 114.72 (+0.54)

Buffett saving a fortune in taxes on Duracell deal
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 2:53PM CST

BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

What The Duracell Deal Says About Procter & Gamble's Valuation
Timberwolf Equity Research - at Seeking Alpha - Thu Nov 13, 1:16PM CST

PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

Duracell: Warren Buffett's Latest Acquisition for Berkshire - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Nov 13, 12:55PM CST
Berkshire Hathaway is buying Duracell from Procter and Gamble in a tax favorable deal worth billions.
PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

One Reason Why Buffett May Have Been Willing to Part With Procter & Gamble
at The Street - Thu Nov 13, 12:24PM CST
Procter & Gamble is one of Warren Buffett's largest holdings. Find out why it was his least-attractive dividend aristocrat holding and ripe to sell.
KO: 42.83 (+0.10), XOM: 94.41 (-0.68), WMT: 83.22 (+0.26), PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

Jim Cramer Explains Why He Likes Berkshire Hathaway's (BRK.A) Acquisition of Duracell
at The Street - Thu Nov 13, 12:05PM CST
TheStreet's Jim Cramer explains why he likes Berkshire Hathaway's (BRK.A) $4.7 billion acquisition of Duracell from Procter & Gamble.
PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

Why Warren Buffett Is Getting P&G's Duracell for Stock Tax-Free
at The Street - Thu Nov 13, 11:10AM CST
Warren Buffett is buying Duracell for much the same reason he has always made acquisitions: for cash flow and earnings.
PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

10 Most Recent Berkshire Hathaway Acquisitions: Duracell, Heinz and More
at The Street - Thu Nov 13, 11:08AM CST
The $3 billion acquisition of Duracell is Berkshire Hathaway's latest big buy. See the last ten by Warren Buffett's company.
PG: 87.90 (-0.21), BRK.B: 144.98 (-0.54), BRK.A: 217,385.00 (-638.00)

Berkshire Hathaway Inc. (BRK.B) Stock Research Links

BRK.B Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...